Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment
PLOS Neglected Tropical Diseases · 07.08.2026 · 20 (8) · e0014617
DOI: 10.1371/journal.pntd.0014617 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 07.08.2026. Verfasst von Juvana M Andrade und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Schistosoma mansoni, Antigens, Helminth, Schistosomiasis mansoni, Helminth Proteins. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Schistosomiasis remains a major neglected tropical disease, and the development of a safe, effective vaccine is a global priority. Sm29, a Schistosoma mansoni surface antigen associated with naturally acquired resistance, has emerged as a promising vaccine candidate; however, its translational advancement requires both high-quality antigen production and evaluation with clinically acceptable adjuvants. Here, we report a Good Laboratory Practice-aligned process for generating tag-free recombinant Sm29 in Escherichia coli , including multi-step anion-exchange chromatography followed by subsequent removal of residual impurities. Analytical validation demonstrated high purity, minimal host cell proteins and residual DNA and low endotoxin levels compliant with international regulatory standards. We then assessed the immunogenicity and protective efficacy of recombinant Sm29 formulated with alum or the squalene-based emulsion (CTVad1) in a murine model of S. mansoni infection. Both formulations elicited robust humoral immune responses, characterized by high titers of total IgG, IgG1, and IgG2c, and moderate levels of IgG3 and IgE anti-Sm29. Regarding cytokines, Sm29 formulated with alum induced a mixed Th1/Th2 immunological profile while Sm29 adjuvanted with CTVad1 engendered a Th2-like response. Following cercarial challenge, CTVad1 + Sm29 or Alum+Sm29 vaccinated mice displayed reduced worm burdens and liver pathology when compared to adjuvant controls. These findings demonstrate that a regulatory-compliant Sm29 antigen, combined with human-compatible adjuvants, induces robust immunity and protection against infection and supports further clinical advancement as a schistosomiasis vaccine candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
- Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
- Departamento de Clínica e Cirurgia Veterinárias, Escola de Veterinária, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
- Centro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Minas Gerais, Brazil.
- Laboratório de Pesquisas Clínicas, Instituto Gonçalo Moniz, FIOCRUZ, Salvador, Brazil.
- Instituto Nacional de Ciências e Tecnologia-Doenças Tropicais, Salvador, Brazil.
ORCID-Profile: Sergio C Oliveira
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Andrade, J. M., Mambelli, F., Gomes, D. S., Souza, M. F. S., Fahel, J. S., Sanches, R. C. O., Marinho, F. V., Salazar, N., Gomes, I. P., Martins, V. T., Carvalho, E. M., de Magalhaes, M. T. Q., Teixeira, S. R., & Oliveira, S. C. (2026). Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment. PLOS Neglected Tropical Diseases, 20(8), e0014617. https://doi.org/10.1371/journal.pntd.0014617
Vancouver
Andrade JM, Mambelli F, Gomes DS, Souza MFS, Fahel JS, Sanches RCO, et al. Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment. PLOS Neglected Tropical Diseases. 2026;20(8):e0014617. doi:10.1371/journal.pntd.0014617
BibTeX
@article{Andrade2026,
author = {Andrade, Juvana M and Mambelli, Fábio and Gomes, Dharliton S and Souza, Monique F S and Fahel, Júlia S and Sanches, Rodrigo C O and Marinho, Fábio V and Salazar, Natália and Gomes, Isabela P and Martins, Vívian T and Carvalho, Edgar M and de Magalhaes, Mariana T Q and Teixeira, Santuza R and Oliveira, Sergio C},
title = {Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
volume = {20},
number = {8},
pages = {e0014617},
doi = {10.1371/journal.pntd.0014617}
}
EUVIMED